Consequently, studies have shown that empagliflozin (EMPA), functioning as a miR-128-3p mimetic, suppresses SP1 expression, reduces CD98hc levels, sensitizes cells to ferroptosis, and may serve as a potential adjunct in BC chemotherapy (Nalla and Khairnar, 2024). Here, SP1 is linked to breast cancer.